Clarus Therapeutics Holdings Inc
NASDAQ:CRXT
Clarus Therapeutics Holdings Inc
Total Liabilities & Equity
Clarus Therapeutics Holdings Inc
Total Liabilities & Equity Peer Comparison
Competitive Total Liabilities & Equity Analysis
Latest Figures & CAGR of Competitors
Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
C
|
Clarus Therapeutics Holdings Inc
NASDAQ:CRXT
|
Total Liabilities & Equity
$51.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Johnson & Johnson
NYSE:JNJ
|
Total Liabilities & Equity
$172B
|
CAGR 3-Years
0%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Liabilities & Equity
$99B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
23%
|
CAGR 10-Years
11%
|
|
Pfizer Inc
NYSE:PFE
|
Total Liabilities & Equity
$221.1B
|
CAGR 3-Years
12%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
Merck & Co Inc
NYSE:MRK
|
Total Liabilities & Equity
$105.8B
|
CAGR 3-Years
5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
0%
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Liabilities & Equity
$63.9B
|
CAGR 3-Years
11%
|
CAGR 5-Years
11%
|
CAGR 10-Years
6%
|
See Also
What is Clarus Therapeutics Holdings Inc's Total Liabilities & Equity?
Total Liabilities & Equity
51.7m
USD
Based on the financial report for Dec 31, 2021, Clarus Therapeutics Holdings Inc's Total Liabilities & Equity amounts to 51.7m USD.
What is Clarus Therapeutics Holdings Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 1Y
167%
Over the last year, the Total Liabilities & Equity growth was 167%.